|
|
供應(yīng) 現(xiàn)貨優(yōu)勢(shì)供應(yīng)CDDO /218600-44-3  |
規(guī) 格: |
毫克、克 |
價(jià) 格: |
5000/ |
數(shù) 量: |
200 |
交貨地: |
廣州 |
發(fā)布時(shí)間: |
2017-09-14 |
有效期: |
255天 |
備 注: |
化學(xué)名稱】: CDDO
【同義詞】: Bardoxolone; RTA 401; 2-Cyano-3,12-dioxooleana-1,9(11)-dien-28-oic Acid;
【CAS 】: 218600-44-3
【分子式】:C31H41O4
【外觀】: 類白色固體
【熔點(diǎn)】: >280oC (dec.)
【分子量】: 491.66
【存儲(chǔ)】:-20˚C Freezer
【溶解性】: 溶于氯仿(略),乙酸乙酯(略),甲醇,DMF等
【應(yīng)用】: CDDO is a synthetic oleanane triterpenoid that exerts multifunctional activities in the control of cellular growth and differentiation. CDDO is capable of activating the transcription factor peroxisome proliferator activator receptor-γ (PPARγ), its apoptotic effects in malignant cells have been shown to occur independently of PPARγ. Bardoxolone was developed as an potential drug for the improvement of hyperglycemia, proteinuria, glomerulus structure, serum creatine, which may in turn be beneficial to treat diabetic kidney diseases, cancer and thromboembolic events.
CDDO是一種合成的通過(guò)多功能活動(dòng)控制細(xì)胞生長(zhǎng)和分化的齊墩果烷型三萜。CDDO被開發(fā)為一種改善高血糖、蛋白尿癥、腎小球結(jié)構(gòu),血清肌酸激酶的潛在性藥物,這可能有利于治療糖尿病、腎臟疾病、癌癥和血栓疾病等。
CDDO (2- 氰基-3 ,12-二氧齊墩果烷-1 ,9(11)- 二烯-28- 酸)及其類似物的合成、藥理和臨床有了較大的進(jìn)展。CDDO 及其衍生物是以齊墩果酸為先導(dǎo)物和前體發(fā)展起來(lái)的,在抗炎和抗癌方面展現(xiàn)出巨大潛力。CDDO-Me已經(jīng)進(jìn)入III 臨床于II 型糖尿病人的慢性腎病治療,在IIb 期臨床試驗(yàn)時(shí)發(fā)現(xiàn),采用CDDO-Me 治療組的腎小球?yàn)V過(guò)率有顯著的提高,CDDO-Im在抗癌方面具有較好的效果。 |
結(jié)構(gòu)式: |
 |
|
|